Glaxo-HGS standoff gets riskier for both sides

Will Human Genome Sciences ($HGS) really get a higher bid by July 16, forcing GlaxoSmithKline ($GSK) to ante up past its $13-per-share bid? Or will HGS's deadline-setting gamble backfire? Maybe both sides should back down and talk, The Wall Street Journal says. Report